Stoke Therapeutics Prepares for Phase 3 Study of Zorevunersen for Dravet Syndrome
Stoke Therapeutics, Inc. (NASDAQ: STOK) recently announced plans to launch a Phase 3 study of zorevunersen, aiming to develop the first disease-modifying treatment for Dravet syndrome. The company disclosed this information in a Form 8-K filing with the Securities and Exchange Commission. The Phase 3 study, named EMPEROR, will assess zorevunersen’s efficacy in reducing major […]
More Stories
Hurricane Watch Issued for Hawaii’s Big Island as Tropical Storm Lala Forms
By Savannah Hulsey Pointer A hurricane watch has been issued for the Big Island of Hawaii as Tropical Storm Lala...
Earnings Are Up Over 50% So Far
By Louis Navellier Through last Friday, 88% of the S&P 500 companies have announced second-quarter results. According to FactSet Earnings...
Trump Orders Navy to Replace Newer Fighter Launch System With Older Steam Catapults
By Timothy Frudd President Donald Trump ordered the Navy on Aug. 13 to return to using steam catapults to launch...
Trade Court Upholds Trump’s Shutdown of $800 De Minimis Duty Exemption
By Matthew Vadum The U.S. Court of International Trade on Aug. 13 upheld the Trump administration’s authority to end the...
Trump Says US Has ‘Total Control’ of Hormuz
By Tom Ozimek President Donald Trump said the United States has “total control” over the Strait of Hormuz, while Energy...
US Annual Inflation Rate Stabilizes in July, Slowing to 3.4 Percent
By Andrew Moran Stabilizing energy prices have helped cool off inflation pressures for the second straight month, new government data...